A rearranged abietane diterpenoid from Clerodendrum mandarinorum inhibits tumor progression of oral squamous cell carcinoma in vitro

Tongue cancer, a prevalent form of oral malignancy, particularly manifests as tongue squamous cell carcinoma (TSCC), which holds the highest incidence among oral squamous cell carcinoma cases, representing 43.4 % of occurrences. Presently, surgical resection stands as the primary treatment for TSCC,...

Full description

Saved in:
Bibliographic Details
Published inArabian journal of chemistry Vol. 17; no. 9; p. 105865
Main Authors Xiao, Kaidi, Zhu, Yuxin, Wu, Yeling, Li, Bing, Cai, Shihao, Qiu, Kaijun, Liu, Chaoge, Ai, Xiaoyu, Li, Xiaohe, Zhou, Honggang, Xiao, Ting, Xie, Chunfeng, Yang, Cheng
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.09.2024
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tongue cancer, a prevalent form of oral malignancy, particularly manifests as tongue squamous cell carcinoma (TSCC), which holds the highest incidence among oral squamous cell carcinoma cases, representing 43.4 % of occurrences. Presently, surgical resection stands as the primary treatment for TSCC, with no effective pharmaceutical interventions identified. This study aims to search for the potential anti-tumor properties and molecular mechanisms of a rearranged abietane diterpenoid extracted from Clerodendrum mandarinorum. Within this investigation, six known rearranged abietane diterpenoids (1–6) were isolated and characterized from C. mandarinorum. Notably, compound 1 demonstrated the most robust inhibitory effect against CAL-27 cells. Pharmacological assays further substantiated that compound 1 significantly restrained the proliferation, migration, and invasion of CAL-27 cells. Moreover, it was revealed that compound 1 directly interacted with TGFβR2, a pivotal receptor in the downstream signaling pathways of TGF-β/Smad and PI3K/AKT. Transcriptome analysis provided additional confirmation of these observations. Overall, our study highlights the promising potential of compound 1 as a therapeutic agent for the treatment of oral squamous cell carcinoma.
ISSN:1878-5352
DOI:10.1016/j.arabjc.2024.105865